Study: NCT01449799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram dose
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram dose
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram dose
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram dose
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 500 microgram dose
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 500 microgram dose
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 500 microgram dose
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 500 microgram dose
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers